News & Events > Press Releases > June 1, 2004

StemCells To Present at BIO 2004 International Convention

PALO ALTO, Calif., June 1 /PRNewswire-FirstCall/ -- Martin McGlynn, President & CEO, and Dr. Ann Tsukamoto, VP R&D, of StemCells, Inc. (Nasdaq: STEM) will participate in the BIO 2004 International Convention. The conference will be held at The Moscone Convention Center in San Francisco, CA from June 6-9, 2004. StemCells, Inc. will give a corporate presentation on June 8, 2004 at 12:00 PM (PDT).

Mr. McGlynn will provide an overview of StemCells Inc.'s tissue derived stem cell technology and will give a progress report on the Company's stated goal of filing its first IND no later than Q1 2005. The purpose of that IND will be to evaluate the Company's proprietary human neural stem cell as therapeutic for Batten Disease, a rare, always fatal neurodegenerative disease that is a member of the Lysosomal Storage Disease family. A review of the Company's current business development strategy will also be presented.

#########################

About StemCells Inc.
StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. Further information about the Company is available on its web site at www.stemcellsinc.com.

Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. ("the Company"). The forward- looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company's ability to obtain the capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the fact that the Company's stem cell technology is at the pre-clinical stage and has not yet led to the development of any proposed product; the uncertainty whether the Company will be able to file an IND in the time it projects and whether the FDA will permit it to proceed to clinical testing; the uncertainty whether the Company will achieve revenues from product sales or become profitable; uncertainties regarding the Company's obligations in regard to its former encapsulated cell therapy facilities in Rhode Island; and other factors that are described in Exhibit 99 to the Company's Annual Report on Form 10-K entitled "Cautionary Factors Relevant to Forward-Looking Statements."

Corporate Contact:		Media / Investor Relations Contact:
StemCells, Inc.			The Investor Relations Group
Martin McGlynn, President & CEO	Janet Vasquez / Jane Lin
650-475-3100, ext 108		212-825-3210

SOURCE  StemCells, Inc.
    -0-                             06/01/2004
/CONTACT:  Martin McGlynn, President & CEO of StemCells, Inc.,
650-475-3100, ext 108;
or
Janet Vasquez or Jane Lin, The Investor Relations
Group, 212-825-3210, for StemCells, Inc./
    /Web site:  http://www.stemcellsinc.com/
    (STEM)

CO:  StemCells, Inc.
ST:  California
IN:  BIO MTC HEA
SU:  TDS

GF 
-- SFTU033 --
1871 06/01/2004 08:00 EDT http://www.prnewswire.com